Berberine (sulfate)

Berberine (sulfate)

• CAS Number: 633-66-9
• UNSPSC Description: Berberine sulfate is an alkaloid isolated from the Chinese herbal medicine Huanglian, as an antibiotic. Berberine sulfate induces reactive oxygen species (ROS) generation and inhibits DNA topoisomerase. Berberine sulfate has antineoplastic properties. The sulfate form improves bioavailability[1][2].
• Target Antigen: Akt; Antibiotic; AP-1; Apoptosis; Autophagy; Bacterial; Caspase; JNK; NF-κB; Parasite; PI3K; Reactive Oxygen Species; Topoisomerase
• Type: Natural Products
• Related Pathways: Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Immunology/Inflammation;MAPK/ERK Pathway;Metabolic Enzyme/Protease;NF-κB;PI3K/Akt/mTOR
• Applications: Cancer-programmed cell death
• Field of Research: Cancer; Infection; Metabolic Disease; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
• Assay Protocol: https://www.medchemexpress.com/berberine-sulfate.html
• Purity: 98.30
• Solubility: DMSO : 0.5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 50 mg/mL (ultrasonic)
• Smiles: COC1=C(OC)C2=C[N+]3=C(C(C(CC3)=C4)=CC5=C4OCO5)C=C2C=C1.O=S(O)([O-])=O
• Molecular Weight: 433.43
• References & Citations: [1]Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62.|[2]Cui HX, et al. Preparation and Evaluation of Antidiabetic Agents of Berberine Organic Acid Salts for Enhancing the Bioavailability. Molecules. 2018 Dec 28;24(1):103.|[3]Boberek JM, et al., Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS One. 2010 Oct 29;5(10):e13745. |[4]Remppis A, et al., Rhizoma Coptidis inhibits LPS-induced MCP-1/CCL2 production in murine macrophages via an AP-1 and NFkappaB-dependent pathway. Mediators Inflamm. 2010;2010:194896.|[5]Bae J, et al., Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells. 2013 Feb;35(2):151-7. |[6]Ye Y, et al., Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Pharmacol. 2021 Apr 26;12:653887.Int Immunopharmacol. 2024 Apr 18:133:112036.|Mol Reprod Dev. 2024 Aug;91(8):e23768.|Acta Pharmacol Sin. 2022 Aug 10.|Appl Biochem Biotechnol. 2023 Dec 28.|Aquaculture. 15 May 2022, 738055.|Biol Pharm Bull. 2022 Jul 20.|Biomed Pharmacother. 2023 Dec 18:170:116012.|BMC Pharmacol Toxicol. 2023 May 11;24(1):29.|Evid-Based Compl Alt. 2021 May 4.|Exp Cell Res. 2020 Aug 1;393(1):112054.|Exp Cell Res. 2024 May 13:114094.|Fish Shellfish Immunol. 2024 Mar 26:109522.|Food Chem Toxicol. 2023 Mar 25;113743.|Gene. 2022 Jan 10;146171.|Hepatol Commun. 2024 Mar 29;8(4):e0405.|Int J Nanomedicine. 2023 Jul 31.|J Bone Miner Metab. 2021 Apr 8.|J Ethnopharmacol. 2024 Apr 24:324:117829.|J Ethnopharmacol. 8 November 2021, 114786.|J Pharm Pharmacol. 2022 May 31;rgac026.|JCI Insight. 2023 Jul 24;8(14):e166306.|Mol Med Rep. 2023 Jan;27(1):17.|Pharm Biol. 2024 Dec;62(1):53-61.|Phytomedicine. 2023 Dec 2, 155247.|Research Square Preprint. 2021 Jun.|Research Square Preprint. 2021 Sep.|Sci Rep. 2022 Oct 17;12(1):17350.|SSRN. 2023 Jan 27.|Aquacult Nutr. 14 Jul 2022.|Biochem Pharmacol. 2021 Apr 27;114576.|Front Pharmacol. 2023 Apr 18:14:1148611.|Inflammopharmacology. 2024 May 17.|Int Immunopharmacol. 2024 May 29:136:112278.|Int Immunopharmacol. 2024 Sep 24;142(Pt B):113227.|J Appl Toxicol. 2024 Jul 9.|Mech Ageing Dev. 2020 Oct;191:111347.|Molecules. 2024 May 14.|Oncologie. 2023 Mar 10.|Phytomedicine. 2023 Jul 17, 154962.|Research Square Preprint. 2021 May.|Research Square Print. 2022 Aug.|Cardiovasc Drugs Ther. 2021 Jul 28.|J Appl Microbiol. 2021 Apr;130(4):1154-1172.|Microbiol Spectr. 2023 Sep 25;e0217023.|Phytomedicine. 2024 Sep 30:135:156111.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: Launched